Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afatinib in EGFR PACC-mutated NSCLC
NCT06062823Phase 2Recruiting
- Sponsor
- National University Hospital
- Start
- Mar 2024
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of afatinib in non-small cell lung cancer (NSCLC), sponsored by National University Hospital. Primary endpoint: Objective Response Rate at 64 weeks. Started Mar 2024; status: recruiting.
02
Drugs
afatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06062823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06062823.